Arndt Vogel, MD, PhD

Articles

The Evolving Treatment Landscape of HCC

August 24th 2022

Closing out their discussion on hepatocellular carcinoma, expert panelists consider future directions in care.

Later-Line IO Therapy for Advanced Hepatocellular Carcinoma

August 17th 2022

Comprehensive insight on later-line immunotherapy and combination strategies available for patients with advanced hepatocellular carcinoma.

Selecting Therapy for Advanced HCC Following Atezo-Bev Failure

August 17th 2022

Expert panelists consider which therapy they would use following failure of atezolizumab + bevacizumab in advanced hepatocellular carcinoma.

Selecting Therapy for Advanced HCC Following TKI Failure

August 10th 2022

Shared insight on which factors help to inform selection of second-line therapy for patients with advanced HCC following lenvatinib failure.

Patient Profile 3: Second-Line Therapy for Advanced HCC

August 10th 2022

Centering discussion on a patient with advanced HCC, expert oncologists consider which agents they would use in the second line following lenvatinib failure.

Frontline Therapy for Advanced HCC: Novel Combination Strategies

August 3rd 2022

Before closing out their discussion on frontline therapy for advanced HCC, expert panelists review other novel combinations under investigation.

Frontline Lenvatinib versus Sorafenib Treatment in Advanced HCC

August 3rd 2022

Comprehensive insight on the selection and use of frontline tyrosine kinase inhibitors for patients with advanced hepatocellular carcinoma.

Role of Hepatitis Status in Selecting Therapy for HCC

July 27th 2022

Expert panelists briefly review how a patient’s hepatitis status may influence treatment selection for advanced hepatocellular carcinoma.

Real-World Selection of Frontline Combination Therapy for Advanced HCC

July 27th 2022

Taking into account respective data from IMbrave150 and HIMALAYA, experts consider how they might select frontline therapy for advanced HCC.

HIMALAYA: Frontline Durvalumab + Tremelimumab in Advanced HCC

July 20th 2022

Shared insight on combination durvalumab + tremelimumab as frontline therapy for advanced HCC in the context of data from the HIMALAYA trial.

Patient Profile 2: Frontline Therapy for Advanced HCC

July 20th 2022

Centering discussion on a patient with advanced-stage HCC, expert panelists discuss the frontline use of atezolizumab + bevacizumab as a standard of care.

Management of HCC: Advances in Biomarkers and Screening

July 13th 2022

A brief review of predictive and prognostic biomarker needs in hepatocellular carcinoma, followed by discussion on screening and detection.

Selection and Use of Systemic Therapy in Intermediate Stage HCC

July 13th 2022

Panelists consider the role of systemic therapy in patients with intermediate-stage HCC who are ineligible for locoregional therapy.

Locoregional Treatment Strategies in Early-/Intermediate-Stage HCC

July 6th 2022

Locoregional Treatment Strategies in Early-/Intermediate-Stage HCC Locoregional Treatment Strategies in Early-/Intermediate-Stage HCC

Early-Stage HCC: What is the Role of Neoadjuvant Therapy?

July 6th 2022

Expert oncologists consider when it would be appropriate to use neoadjuvant therapy for early-/intermediate-stage hepatocellular carcinoma.

Dr. Vogel on the OS Benefit of Durvalumab/Tremelimumab in Unresectable HCC

June 30th 2022

Arndt Vogel, MD, discusses the outcomes of the phase 3 HIMALAYA trial in unresectable hepatocellular carcinoma.

Early-Stage HCC: Role of Adjuvant Therapy

June 29th 2022

A brief discussion on the risks of neoadjuvant immunotherapy in early-/intermediate-stage HCC with regard for liver transplantation candidacy.

Patient Profile 1: Resection for Early/Intermediate Stage HCC

June 29th 2022

Centering discussion on a patient with early/intermediate-stage HCC, expert panelists consider the roles of transplant, resection, and adjuvant therapy, respectively.

Dr. Vogel on the Utility of Frontline Lenvatinib or Sorafenib in HCC

September 4th 2021

Arndt Vogel, MD, discusses the utility of frontline lenvatinib or sorafenib in hepatocellular carcinoma.

Dr. Vogel on the FIGHT-202 Trial in Cholangiocarcinoma

September 28th 2019

Arndt Vogel, MD, PhD, professor of gastrointestinal oncology, Hannover Medical School, discusses the results of the open-label, single-arm phase II FIGHT-202 trial in cholangiocarcinoma.